Research Progress on the Combination Therapy of EGFR-TKIs and Metformin 
in Acquired Resistance to EGFR-TKIs in Non-small Cell Lung Cancer

Research Progress on the Combination Therapy of EGFR-TKIs and Metformin 
in Acquired Resistance to EGFR-TKIs in Non-small Cell Lung Cancer

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) targeting EGFR are effective in EGFR mutation-positive non-small cell lung cancer (NSCLC) patients, but drug resistance is inevitable. With the application and expansion of individualized and combined therapy, more and more stud...

Full description

Bibliographic Details
Main Authors: Jiamin WANG, Pan LIU, Lisha YING, Rui ZHU, Chaodan YANG, Ying YANG, Dan SU
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2023-11-01
Series:Chinese Journal of Lung Cancer
Subjects:
epidermal growth factor receptor-tyrosine kinase inhibitors
metformin
targeted therapy
lung neoplasms
combined therapy
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2023.106.22
Description
Summary:Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) targeting EGFR are effective in EGFR mutation-positive non-small cell lung cancer (NSCLC) patients, but drug resistance is inevitable. With the application and expansion of individualized and combined therapy, more and more studies have shown that combined administration of Metformin effectively solves the problem of acquired drug resistance to EGFR-TKIs in clinical treatment and prolongs the survival of patients with NSCLC. EGFR-TKIs combined with Metformin is expected to be the treatment method of choice for NSCLC patients with EGFR-TKIs resistance. This paper intends to summarize the research progress of EGFR-TKIs combined with Metformin in the treatment of EGFR-TKIs acquired resistance in NSCLC, in order to provide a new idea for the treatment of NSCLC patients with acquired resistance to EGFR-TKIs.
ISSN:1009-3419
1999-6187

Similar Items